Pharming Receives Positive European Committee Opinion for Immunodeficiency Treatment; Shares Up Pre-Bell
MT Newswires Live
Mar 27
Pharming Group (PHAR) said Friday a European Medicines Agency committee recommended marketing authorization for its Joenja drug to treat activated phosphoinositide 3-kinase delta syndrome, a rare immunodeficiency in patients aged 12 years and above.
The European Commission is expected to issue a final decision within about two months.
The positive recommendation is supported by data from phase 2/3 clinical trial demonstrating a "statistically significant" impact on immune dysregulation and immunodeficiency, the company said.
Pharming shares were up 5.4% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.